10.91
前日終値:
$8.06
開ける:
$8.22
24時間の取引高:
2.97M
Relative Volume:
36.71
時価総額:
$3.79M
収益:
$10.48M
当期純損益:
$-37.74M
株価収益率:
-0.6741
EPS:
-16.1846
ネットキャッシュフロー:
$-29.03M
1週間 パフォーマンス:
+98.00%
1か月 パフォーマンス:
+101.66%
6か月 パフォーマンス:
-60.68%
1年 パフォーマンス:
-95.72%
Jaguar Health Inc Stock (JAGX) Company Profile
名前
Jaguar Health Inc
セクター
電話
415-371-8300
住所
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
JAGX
Jaguar Health Inc
|
10.91 | 3.79M | 10.48M | -37.74M | -29.03M | -16.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
Jaguar Health Inc (JAGX) 最新ニュース
Press Release Distribution & PR Platform - ACCESS Newswire
Jaguar Health's (JAGX) Crofelemer Shows Promise in Breast Cancer Subgroup - GuruFocus
Jaguar Health Presents at Elite Ped-GI Congress 2025 - TipRanks
Jaguar Health (JAGX) Reports Progress in Rare Disease Drug Trial - GuruFocus
Jaguar Health's (JAGX) Crofelemer Trial Shows Promise for Rare Disorders | JAGX Stock News - GuruFocus
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | JAGX Stock News - GuruFocus
First-Ever MVID Treatment? Crucial Trial Data for Orphan Drug Crofelemer Coming to Elite Congress - Stock Titan
Jaguar Health to present results from OnTarget study in breast cancer patients - Yahoo Finance
Jaguar Health to discuss breast cancer treatment with FDA By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Advances OnTarget Study with Key Presentati - GuruFocus
Jaguar Health to discuss breast cancer treatment with FDA - Investing.com
Jaguar Health Announces Significant Results in Breast Cancer Pat - GuruFocus
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting | JAGX Stock News - GuruFocus
Game-Changing Results: New Cancer Drug Shows Remarkable Success in Breast Cancer Patients - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - MSN
Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea - ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting - GuruFocus
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - markets.businessinsider.com
Revolutionary Pain Relief: New FDA-Approved Treatment Transforms Cancer Care Experience - Stock Titan
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire
Jaguar Health (NASDAQ:JAGX) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
Jaguar Animal Health Secures $3.448M in Private Placement - TipRanks
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Expands Workforce: New Stock Grants Signal Growth Strategy - Stock Titan
Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs - MSN
Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product - ACCESS Newswire
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health completes $3.4 million private placement By Investing.com - Investing.com South Africa
Jaguar Health completes $3.4 million private placement - Investing.com
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Jaguar Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Jaguar Health Advances Plant-Based Pharmaceuticals - TipRanks
Jaguar Health’s Earnings Call: Growth Amid Challenges - TipRanks
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 - Investing.com Canada
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline By Investing.com - Investing.com South Africa
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline - Investing.com Australia
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 By Investing.com - Investing.com South Africa
Jaguar Health Inc (JAGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):